Literature DB >> 21909140

Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer.

A Urbanucci1, B Sahu, J Seppälä, A Larjo, L M Latonen, K K Waltering, T L J Tammela, R L Vessella, H Lähdesmäki, O A Jänne, T Visakorpi.   

Abstract

Androgen receptor (AR) is overexpressed in the majority of castration-resistant prostate cancers (CRPCs). Our goal was to study the effect of AR overexpression on the chromatin binding of the receptor and to identify AR target genes that may be important in the emergence of CRPC. We have established two sublines of LNCaP prostate cancer (PC) cell line, one overexpressing AR 2-3-fold and the other 4-5-fold compared with the control cells. We used chromatin immunoprecipitation (ChIP) and deep-sequencing (seq) to identify AR-binding sites (ARBSs). We found that the number of ARBSs and the AR-binding strength were positively associated with the level of AR when cells were stimulated with low concentrations of androgens. In cells overexpressing AR, the chromatin binding of the receptor took place in 100-fold lower concentration of the ligand than in control cells. We confirmed the association of AR level and chromatin binding in two PC xenografts, one containing AR gene amplification with high AR expression, and the other with low expression. By combining the ChIP-seq and expression profiling, we identified AR target genes that are upregulated in PC. Of them, the expression of ZWINT, SKP2 (S-phase kinase-associated protein 2 (p45)) and FEN1 (flap structure-specific endonuclease 1) was demonstrated to be increased in CRPC, while the expression of SNAI2 was decreased in both PC and CRPC. FEN1 protein expression was also associated with poor prognosis in prostatectomy-treated patients. Finally, the knock-down of FEN1 with small interfering RNA inhibited the growth of LNCaP cells. Our data demonstrate that the overexpression of AR sensitizes the receptor binding to chromatin, thus, explaining how AR signaling pathway is reactivated in CRPC cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21909140     DOI: 10.1038/onc.2011.401

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  60 in total

1.  A hormone-DNA repair circuit governs the response to genotoxic insult.

Authors:  Jonathan F Goodwin; Matthew J Schiewer; Jeffry L Dean; Randy S Schrecengost; Renée de Leeuw; Sumin Han; Teng Ma; Robert B Den; Adam P Dicker; Felix Y Feng; Karen E Knudsen
Journal:  Cancer Discov       Date:  2013-09-11       Impact factor: 39.397

Review 2.  Maintaining and reprogramming genomic androgen receptor activity in prostate cancer.

Authors:  Ian G Mills
Journal:  Nat Rev Cancer       Date:  2014-03       Impact factor: 60.716

3.  Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression.

Authors:  Pei-Chun Lin; Ya-Lin Chiu; Samprit Banerjee; Kyung Park; Juan Miguel Mosquera; Eugenia Giannopoulou; Pedro Alves; Ashutosh K Tewari; Mark B Gerstein; Himisha Beltran; Ari M Melnick; Olivier Elemento; Francesca Demichelis; Mark A Rubin
Journal:  Cancer Res       Date:  2012-12-11       Impact factor: 12.701

4.  Slug, a unique androgen-regulated transcription factor, coordinates androgen receptor to facilitate castration resistance in prostate cancer.

Authors:  Kaijie Wu; Crystal Gore; Lin Yang; Ladan Fazli; Martin Gleave; Rey-Chen Pong; Guanghua Xiao; Linlin Zhang; Eun-Jin Yun; Shu-Fen Tseng; Payal Kapur; Dalin He; Jer-Tsong Hsieh
Journal:  Mol Endocrinol       Date:  2012-06-28

5.  Reducing the risk of false discovery enabling identification of biologically significant genome-wide methylation status using the HumanMethylation450 array.

Authors:  Haroon Naeem; Nicholas C Wong; Zac Chatterton; Matthew K H Hong; John S Pedersen; Niall M Corcoran; Christopher M Hovens; Geoff Macintyre
Journal:  BMC Genomics       Date:  2014-01-22       Impact factor: 3.969

6.  Association between age-related reductions in testosterone and risk of prostate cancer-An analysis of patients' data with prostatic diseases.

Authors:  Kai Wang; Xinguang Chen; Victoria Y Bird; Travis A Gerke; Todd M Manini; Mattia Prosperi
Journal:  Int J Cancer       Date:  2017-07-24       Impact factor: 7.396

Review 7.  Rationale for the development of alternative forms of androgen deprivation therapy.

Authors:  Sangeeta Kumari; Dhirodatta Senapati; Hannelore V Heemers
Journal:  Endocr Relat Cancer       Date:  2017-05-31       Impact factor: 5.678

8.  Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes.

Authors:  Michael A Augello; Craig J Burd; Ruth Birbe; Christopher McNair; Adam Ertel; Michael S Magee; Daniel E Frigo; Kari Wilder-Romans; Mark Shilkrut; Sumin Han; Danielle L Jernigan; Jeffry L Dean; Alessandro Fatatis; Donald P McDonnell; Tapio Visakorpi; Felix Y Feng; Karen E Knudsen
Journal:  J Clin Invest       Date:  2012-12-21       Impact factor: 14.808

9.  The ETS domain transcription factor ELK1 directs a critical component of growth signaling by the androgen receptor in prostate cancer cells.

Authors:  Mugdha Patki; Venkatesh Chari; Suneethi Sivakumaran; Mesfin Gonit; Robert Trumbly; Manohar Ratnam
Journal:  J Biol Chem       Date:  2013-02-20       Impact factor: 5.157

10.  Nuclear export signal of androgen receptor (NESAR) regulation of androgen receptor level in human prostate cell lines via ubiquitination and proteasome-dependent degradation.

Authors:  Yanqing Gong; Dan Wang; Javid A Dar; Prabhpreet Singh; Lara Graham; Weijun Liu; Junkui Ai; Zhongcheng Xin; Yinglu Guo; Zhou Wang
Journal:  Endocrinology       Date:  2012-10-05       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.